Severe pneumonia caused by human adenovirus type 55 in children

Dongwei Zhang1, Yi Chen2, Tingting Shi1

  • 1Department of Respiratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.

Frontiers in Pediatrics
|October 31, 2022
PubMed

Insights

Human adenovirus type 55 (HAdV-55) can cause fatal pneumonia in children, often with co-infections. This study highlights HAdV-55 as a significant cause of severe pediatric pneumonia and potential long-term complications like post-infectious bronchiolitis obliterans.

Area of Science:

  • Pediatric Infectious Diseases
  • Virology
  • Respiratory Medicine

Background:

  • Human adenovirus type 55 (HAdV-55) is an emerging pathogen causing severe pneumonia in adults.
  • Limited research exists on HAdV-55's impact on pediatric severe pneumonia.

Purpose of the Study:

  • To investigate the clinical characteristics and outcomes of severe pneumonia caused by HAdV-55 in children.
  • To identify risk factors and complications associated with HAdV-55 pediatric pneumonia.

Main Methods:

  • Retrospective review of pediatric patients with severe pneumonia from 2013-2020.
  • Detection of human adenovirus (HAdV) using RT-PCR in respiratory samples.
  • Identification of HAdV-55 by PCR amplification of hexon gene hypervariable regions.

Main Results:

  • HAdV-55 was identified in 9 pediatric patients with severe (3) or critical (6) pneumonia, with no underlying conditions.
  • Common symptoms included fever and cough; coinfections with bacteria, Mycoplasma pneumoniae, and fungi were frequent (6/9 patients).
  • Critical cases experienced prolonged mechanical ventilation (median 10 days), high mortality (3/3), and complications including plastic bronchitis (PB) and post-infectious bronchiolitis obliterans (PIBO) in survivors.

Conclusions:

  • HAdV-55 is a significant cause of severe and fatal pneumonia in previously healthy children.
  • Coinfections and complications like PB and PIBO are associated with HAdV-55, indicating a poorer prognosis.
  • HAdV-55 warrants attention as a critical pathogen in pediatric respiratory infections, particularly those leading to PIBO.
Abstract

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
302
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
429
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
363
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
426
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
319